$MLYS
Mineralys Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000193341424000057 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.121M
YoY Change 62.19%
% of Gross Profit
Research & Development $53.99M
YoY Change 139.94%
% of Gross Profit
Depreciation & Amortization $11.00K
YoY Change
% of Gross Profit
Operating Expenses $60.11M
YoY Change 128.77%
Operating Profit -$60.11M
YoY Change 128.77%
Interest Expense $3.774M
YoY Change 7.43%
% of Operating Profit
Other Income/Expense, Net $3.764M
YoY Change 7.14%
Pretax Income -$56.34M
YoY Change 147.55%
Income Tax
% Of Pretax Income
Net Earnings -$56.34M
YoY Change 147.55%
Net Earnings / Revenue
Basic Earnings Per Share -$1.13
Diluted Earnings Per Share -$1.13
COMMON SHARES
Basic Shares Outstanding 49.77M shares 49.73M shares
Diluted Shares Outstanding 49.82M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $263.6M
YoY Change 3.88%
Cash & Equivalents $97.27M
Short-Term Investments $166.3M
Other Short-Term Assets $4.129M
YoY Change -64.45%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $267.7M
YoY Change 0.89%
LONG-TERM ASSETS
Property, Plant & Equipment $69.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $452.0K
YoY Change 786.27%
Total Long-Term Assets $521.0K
YoY Change -95.72%
TOTAL ASSETS
Total Short-Term Assets $267.7M
Total Long-Term Assets $521.0K
Total Assets $268.3M
YoY Change -3.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.106M
YoY Change -44.27%
Accrued Expenses $28.22M
YoY Change 254.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.32M
YoY Change 131.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $31.32M
Total Long-Term Liabilities $0.00
Total Liabilities $31.32M
YoY Change 131.27%
SHAREHOLDERS EQUITY
Retained Earnings -$253.6M
YoY Change 152.84%
Common Stock $5.000K
YoY Change 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $236.9M
YoY Change
Total Liabilities & Shareholders Equity $268.3M
YoY Change -3.35%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$56.34M
YoY Change 147.55%
Depreciation, Depletion And Amortization $11.00K
YoY Change
Cash From Operating Activities -$50.19M
YoY Change 163.71%
INVESTING ACTIVITIES
Capital Expenditures $37.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $79.64M
YoY Change 1887.57%
Cash From Investing Activities $79.61M
YoY Change 1886.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.000K
YoY Change -100.54%
NET CHANGE
Cash From Operating Activities -50.19M
Cash From Investing Activities 79.61M
Cash From Financing Activities -1.000K
Net Change In Cash 29.42M
YoY Change -298.23%
FREE CASH FLOW
Cash From Operating Activities -$50.19M
Capital Expenditures $37.00K
Free Cash Flow -$50.22M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001933414
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1966887
dei Entity Address Address Line1
EntityAddressAddressLine1
150 N. Radnor Chester Rd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite F200
dei Entity Address City Or Town
EntityAddressCityOrTown
Radnor
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19087
dei City Area Code
CityAreaCode
888
dei Local Phone Number
LocalPhoneNumber
378-6240
dei Security12b Title
Security12bTitle
Common stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
MLYS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49304000 usd
CY2024Q3 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
166329000 usd
CY2023Q4 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
187263000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4129000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12536000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
267732000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
249103000 usd
CY2024Q3 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent
0 usd
CY2023Q4 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent
2482000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1276000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12141000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
285010000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1578000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22760000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
264012000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
241154000 usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
MINERALYS THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2872000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-41014000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
290095000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49768669 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97274000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
69000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
452000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
51000 usd
CY2024Q3 us-gaap Assets
Assets
268253000 usd
CY2023Q4 us-gaap Assets
Assets
251636000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3106000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
601000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9881000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10482000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41133916 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41133916 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
490499000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
365858000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-253572000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124708000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
236932000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
241154000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
268253000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
251636000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53985000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22499000 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28215000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
124012000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46676000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6121000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3774000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16624000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10270000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
60106000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
26273000 usd
us-gaap Operating Expenses
OperatingExpenses
140636000 usd
us-gaap Operating Expenses
OperatingExpenses
56946000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-60106000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26273000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-140636000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-56946000 usd
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3774000 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3513000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
11779000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
9435000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3764000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3513000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11772000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9437000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-56342000 usd
us-gaap Net Income Loss
NetIncomeLoss
-128864000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47509000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.36
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49815186 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49815186 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34872287 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34872287 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-52269000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
158644000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
201359000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
749000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-12608000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
295875000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
149000 usd
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0926
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
31321000 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49755946 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49755946 shares
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22760000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.13
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.13
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.68
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39930748 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39930748 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48063638 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48063638 shares
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
184000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
116059000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2191000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-31508000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
328045000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
54000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
138000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3139000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-56342000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
236932000 usd
us-gaap Net Income Loss
NetIncomeLoss
-128864000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47509000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
8068000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4799000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8202000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3603000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-326000 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
655000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-8068000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8308000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
20837000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5476000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-99471000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52192000 usd
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
309515000 usd
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
274883000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
341000000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
122500000 usd
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
96000 usd
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31389000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-152383000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
116059000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
243000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
184000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
138000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
388000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
202990000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
116052000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
203174000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
47970000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1401000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49304000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87701000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97274000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86300000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
159180000 usd
CY2024Q3 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
166300000 usd
CY2024Q3 us-gaap Investments And Cash
InvestmentsAndCash
263600000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-253600000 usd
CY2024Q3 us-gaap Investments And Cash
InvestmentsAndCash
263600000 usd
us-gaap Net Income Loss
NetIncomeLoss
-128900000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-99500000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
498800000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates </span></div>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Estimates have been used in the following areas, among others: research and development accruals, fair value of the Company’s common stock prior to the closing of the Company’s IPO, and income taxes.
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2024Q3 us-gaap Cash
Cash
501000 usd
CY2023Q4 us-gaap Cash
Cash
643000 usd
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
96773000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
48661000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97274000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49304000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. Financial instruments that </span></div>potentially subject the Company to concentrations of credit risk primarily consist of cash balances in several accounts with three financial institutions which, from time to time, are in excess of federally insured limits.
CY2024Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
400000 usd
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5128220 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3616151 shares
CY2024Q3 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
166329000 usd
CY2024Q3 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
166446000 usd
CY2023Q4 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
187263000 usd
CY2023Q4 us-gaap Debt Securities Held To Maturity Fair Value Current
DebtSecuritiesHeldToMaturityFairValueCurrent
187293000 usd
CY2023Q4 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent
2482000 usd
CY2023Q4 us-gaap Debt Securities Held To Maturity Fair Value Noncurrent
DebtSecuritiesHeldToMaturityFairValueNoncurrent
2486000 usd
CY2023Q4 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
189745000 usd
CY2023Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
189779000 usd
CY2024Q3 mlys Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
24080000 usd
CY2023Q4 mlys Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
7122000 usd
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2104000 usd
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1599000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2031000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1160000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28215000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9881000 usd
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8461768 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
50000000 shares
CY2024Q1 mlys Sale Of Warrants Number Of Shares Issued In Transaction
SaleOfWarrantsNumberOfSharesIssuedInTransaction
549755 shares
CY2024Q1 mlys Sale Of Warrants Price Per Share
SaleOfWarrantsPricePerShare
13.499
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4677742 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2450553 shares
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3139000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1578000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8202000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3603000 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001933414-24-000057-index-headers.html Edgar Link pending
0001933414-24-000057-index.html Edgar Link pending
0001933414-24-000057.txt Edgar Link pending
0001933414-24-000057-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mlys-20240930.htm Edgar Link pending
mlys-20240930.xsd Edgar Link pending
mlys3q2410qex311.htm Edgar Link pending
mlys3q2410qex312.htm Edgar Link pending
mlys3q2410qex321.htm Edgar Link pending
mlys3q2410qex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
mlys-20240930_def.xml Edgar Link unprocessable
mlys-20240930_lab.xml Edgar Link unprocessable
mlys-20240930_pre.xml Edgar Link unprocessable
mlys-20240930_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mlys-20240930_cal.xml Edgar Link unprocessable